UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of February 2024
Commission File Number 001-38370
CollPlant Biotechnologies Ltd.
(Exact name of registrant as specified in its charter)
4 Oppenheimer St, Weizmann Science Park
Rehovot 7670104, Israel
(Address of principal executive office)
Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒
Form 40-F ☐
On February 15, 2023, CollPlant
Biotechnologies Ltd. issued a press release entitled “CollPlant Issues Letter to Shareholders”. A copy of the press release
is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Attached hereto and incorporated by reference herein are the following
exhibits:
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
|
COLLPLANT BIOTECHNOLOGIES LTD. |
Date: February 15, 2024 |
|
|
|
|
By: |
/s/
Eran Rotem |
|
|
Name: |
Eran Rotem |
|
|
Title: |
Deputy CEO and
Chief Financial Officer |
Exhibit 99.1
CollPlant Issues Letter to Shareholders
Rehovot, Israel, February 15, 2024 – CollPlant Biotechnologies
(Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived
collagen for tissue regeneration and organ manufacturing, is pleased to issue the following letter from its Chief Executive Officer, Yehiel
Tal.
Dear Shareholders,
As we look toward a promising and exciting year ahead, I am proud to
reflect on CollPlant’s main achievements throughout 2023. We leveraged our pioneering collagen-based platform and dynamic workforce to
strengthen existing business collaborations, as well as to initiate and advance new opportunities. We continued to develop products with
safety and performance advantages that we believe will lead to further innovation in the fields of regenerative and aesthetic medicine.
We are excited with our progress while remaining extremely focused on advancing our goal to become a global leader in these fields.
Collaborations
During 2023, we made significant progress with our development partner,
AbbVie, to advance our dermal and soft tissue filler toward commercialization. Furthermore, we continue to be engaged in partnering discussions
with several industry leaders seeking to leverage our rhCollagen technology and expertise in 3D bioprinting to develop therapeutics and
medical applications.
AbbVie
Our long-term collaboration with AbbVie to develop a paradigm-shifting
regenerative dermal and soft tissue filler continues to advance. In June of last year, we announced the achievement of an important milestone
under this collaboration which triggered a $10 million payment from AbbVie to CollPlant. Per CollPlant’s agreement with AbbVie,
CollPlant has the potential to receive additional milestones and option products payments, as well as receive meaningful royalties on
product sales. AbbVie continues to advance the filler program which is now in clinical studies.
Stratasys
In April of last year, we announced a joint development and commercialization
agreement with Stratasys Ltd. to collaborate on the development of a solution to bio-fabricate human tissues and organs using Stratasys’
P3 technology-based bioprinter and CollPlant’s rh-Collagen-based bioinks. The first project focuses on the development of an industrial-scale
solution for CollPlant’s regenerative breast implants program. The new bioprinter, based on Stratasys’ precise P3™ 3D printing
technology in combination with CollPlant’s flagship bioinks, is designed to enable the production of CollPlant’s state of the art
breast implants, which are being developed to regenerate an individual’s natural breast tissue without eliciting immune response,
providing a potentially revolutionary alternative for both aesthetic and reconstructive procedures.
Under the agreement, both companies have agreed to cross-promote each
other’s bioprinting products. Stratasys’ bioprinter will be offered to customers together with CollPlant’s bioinks,
and similarly Stratasys’ bioprinter will be offered to CollPlant’s business partners and customers.
Products Pipeline
I am proud to share with you a few important highlights from this past
year related to our products pipeline, which targets large commercial opportunities in both, medical aesthetics and personalized medicine
markets. At the cornerstone of our success lies the many advantages of our high-performance non-animal, recombinant human (rh)Collagen.
Regenerative Breast Implants
One of our most exciting products in development is our regenerative
breast implants, addressing the $2.6 billion global breast implant market. Additionally, breast reconstruction and augmentation procedures
represent the second most common plastic surgery procedure performed worldwide today. The most common breast augmentation or reconstruction
procedures today are based on synthetic silicone breast implantations, an artificial substitution for natural regenerated tissue with
risks of complications.
Currently, there are no commercial products that allow regeneration
of soft tissues such as the breast. In the U.S. alone, hundreds of thousands of people per year experience adverse events that range from
autoimmune symptoms to the very serious breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). CollPlant’s breast implants
that are comprised of the Company’s proprietary plant-derived rhCollagen and other biomaterials, are expected to regenerate breast tissue
without eliciting immune response, and thus may provide a revolutionary alternative for aesthetic and reconstructive procedures, including
postmastectomy for cancer patients.
In January of last year, we announced the successful completion of
a large animal study for our recombinant human collagen (rhCollagen)-based 3D bioprinted regenerative breast implants. The preclinical
study demonstrated progressive stages of tissue regeneration after three months, as highlighted by the formation of maturing connective
tissue and neovascular networks within the implants, with no adverse events reported. This study was followed by additional large animal
studies that were intended to further optimize the implant design and composition. New tissue formation and neovascularization with no
adverse tissue reactions were demonstrated confirming previous results.
Supported by these promising results, in December 2023, we initiated
a large-animal study to evaluate commercial-size,3D-bioprinted, regenerative breast implants. This study will be used to obtain data that
will be used to support subsequent human studies and future product commercialization.
The achievements we demonstrated to date take us another step forward
in the development of a revolutionary alternative to silicone implants for aesthetic and reconstructive procedures.
Gut-on-a-Chip Tissue Model
CollPlant decided in 2022 to expand into the promising field of personalized
medicine. Our lead program in this space is our gut-on-a-chip program that is addressing the need to provide therapeutic choices for inflammatory
bowel diseases. Our specific focus is on ulcerative colitis, or UC.
We are developing a bioprinted human intestine model that can be used
in drug discovery and personalized treatment of UC. The 3D bioprinted model is designed to emulate the human intestine tissue in order
to allow medical professionals to identify drug targets and personalized therapeutic responses that can lead to improved patient outcomes.
We remain extremely excited about the prospects for this program and
plan to provide an update with the next steps for this program as we enter the next phase of development.
Intellectual Property
In November of last year, we announced that the U.S. Patent and Trademark
Office has granted a patent that covers CollPlant’s photocurable dermal filler product candidate, being developed for the aesthetics market.
The U.S. Patent (No. 11,801,329) is directed, among other things, to
a method of filling tissue space under the epidermis by introducing a polymerizable filler solution into the tissue space and applying
external light to induce in-situ polymerization. This newly issued patent is related to CollPlant’s photocuring technology and serves
as the basis of our photocurable dermal filler product pipeline currently under development. The polymerizable solution injected into
the tissue space is comprised of a chemically modified recombinant human collagen (rhCollagen) and other constituents such as hyaluronic
acid.
This patent represents an integral part of the Company’s strategy to
expand the uses for its novel, rhCollagen technology into new, high-value markets. The U.S. is one of CollPlant’s strategic target markets,
and we see the strengthening of our intellectual property in this territory as a significant achievement.
In addition to its superior skin lifting capacity, the photocurable
filler is designed to enable tissue regeneration and tissue contouring ability. This issued patent expiring in 2039 provides coverage
for a regenerative photocurable dermal filler with contouring capabilities and we believe this will strengthen our position in the market
for many years to come.
Corporate Responsibility
Our rhCollagen production process utilizes plant-based genetic engineering
technology. This approach eliminates the need for traditional animal-derived collagen sources, reducing the environmental strain associated
with traditional methods and promoting more ethical and sustainable practices.
In the second quarter of 2023, CollPlant hired a dedicated expert to
lead our Environment, Social and Governance (ESG) effort. Our goal was to identify CollPlant’s strengths in the areas of ESG that
are already in line with our mission and communicate these practices to business partners and the public.
In line with this initiative,
in September last year, CollPlant announced that it joined the United Nations Global Compact, the world’s largest initiative for sustainable
and responsible corporate governance. As a new participant of this voluntary leadership platform, CollPlant strengthens its commitment
to operate sustainably as it is also producing sustainable alternatives to the regenerative and aesthetics medicine products and technologies
that currently exist.
Consistent with our mission of helping people live longer, healthier
lives through regenerative medicine, we are committed to supporting a more sustainable ecosystem that benefits all stakeholders, including
patients, our employees, and our shareholders.
In Closing
Tissue and organ shortage is a major medical challenge arising from
a combination of donor scarcity and patient rejection. As technologies evolve with 3D bioprinting technology, we believe this will enable
CollPlant to address the challenge by utilizing our rhCollagen to help to create an unlimited supply of tissues and organs.
Additionally, as we develop tissue models that can mimic a variety
of human disease conditions, this will be a driver for our strategic expansion into personalized medicine.
In 2024, we plan to further advance and expand our diverse portfolio
of innovative products and value-creating partnerships, alongside our commitment to support a more sustainable and equitable world.
Especially this challenging year, I would like to thank our employees
– who continue to show an unwavering commitment to improving patients’ lives - for their dedication and passion, which has
launched us to the next level of performance and closer towards becoming the leaders in regenerative medicine.
Finally, and importantly, I would also like to thank my fellow shareholders
for their continued trust and support for CollPlant’s mission to become a global leader in regenerative and aesthetic medicine.
With Appreciation and Optimism,
Yehiel Tal
Chief Executive Officer,
CollPlant Biotechnologies
About CollPlant
CollPlant is a regenerative and aesthetic medicine
company focused on 3D bioprinting of tissues and organs, and medical aesthetics. The Company’s products are based on its rhCollagen (recombinant
human collagen) produced with CollPlant’s proprietary plant based genetic engineering technology. These products address indications for
the diverse fields of tissue repair, aesthetics, and organ manufacturing, and are ushering in a new era in regenerative and aesthetic
medicine.
In 2021 CollPlant entered into a development and
global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the dermal
filler market.
For more information
about CollPlant, visit: http://www.collplant.com.
Forward-Looking Statements
This communication may include forward-looking statements. Forward-looking
statements may include, but are not limited to, statements relating to CollPlant’s objectives plans and strategies, as well as statements,
other than historical facts, that address activities, events or developments that CollPlant intends, expects, projects, believes or anticipates
will or may occur in the future. These statements are often characterized by terminology such as “believes,” “hopes,”
“may,” “anticipates,” “should,” “intends,” “plans,” “will,” “expects,”
“estimates,” “projects,” “positioned,” “strategy” and similar expressions and are based on assumptions
and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments
and other factors believed to be appropriate.
Forward-looking statements are not guarantees of future performance
and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such
statements. Many factors could cause CollPlant’s actual activities or results to differ materially from the activities and results anticipated
in forward-looking statements, including, but not limited to, the following: the Company’s history of significant losses, its need to
raise additional capital and its inability to obtain additional capital on acceptable terms, or at all; the Company’s expectations regarding
the timing and cost of commencing pre-clinical and clinical trials with respect to breast implants, tissues and organs which are based
on its rhCollagen based BioInk and other products for medical aesthetics, and specifically the Company’s ability to initiate its next
large-animal study for its breast implants in a timely manner, or at all; the Company’s ability to develop a printing solution for
its breast implants program, or at all; the Company’s ability to obtain favorable pre-clinical and clinical trial results; regulatory
action with respect to rhCollagen based BioInk and medical aesthetics products including but not limited to acceptance of an application
for marketing authorization review and approval of such application, and, if approved, the scope of the approved indication and labeling;
commercial success and market acceptance of the Company’s rhCollagen based products, in 3D bioprinting and medical aesthetics; the Company’s
ability to establish sales and marketing capabilities or enter into agreements with third parties and its reliance on third party distributors
and resellers; the Company’s ability to establish and maintain strategic partnerships and other corporate collaborations, including its
partnership with AbbVie and its ability to continue to receive milestone and royalties payments under the AbbVie agreement; the Company’s
reliance on third parties to conduct some or all aspects of its product manufacturing; the scope of protection the Company is able to
establish and maintain for intellectual property rights and the Company’s ability to operate its business without infringing the intellectual
property rights of others; current or future unfavorable economic and market conditions and adverse developments with respect to financial
institutions and associated liquidity risk; the impact of competition and new technologies; general market, political, and economic conditions
in the countries in which the Company operates, including, with respect to the Israel- Hamas war, projected capital expenditures and liquidity,
changes in the Company’s strategy, and litigation and regulatory proceedings. More detailed information about the risks and uncertainties
affecting CollPlant are contained under the heading “Risk Factors” included in CollPlant’s most recent annual report on Form
20-F filed with the SEC, and in other filings that CollPlant has made and may make with the SEC in the future. The forward-looking statements
contained in this press release are made as of the date of this press release and reflect CollPlant’s current views with respect to future
events, and CollPlant does not undertake and specifically disclaims any obligation to update or revise any forward-looking statements,
whether as a result of new information, future events, or otherwise.
Contact at CollPlant:
Eran Rotem
Deputy CEO & CFO
Tel: + 972-73-2325600
Eran@collplant.com
4
CollPlant Biotechnologies (NASDAQ:CLGN)
Historical Stock Chart
From Oct 2024 to Nov 2024
CollPlant Biotechnologies (NASDAQ:CLGN)
Historical Stock Chart
From Nov 2023 to Nov 2024